Alerts
COVID-19 update
See our updated visitor policy, which allows 1 visitor per patient during exams only and includes masking for all. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

Phase I/II Study of Dabrafenib, Trametinib, and Navitoclax in BRAF Mutant Melanoma Phase I and II and Other Solid Tumors Phase I Only.

Brief Summary

Type:
Melanoma

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT01989585

Study #:
STUDY00146134

Start Date:
Nov 09, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT01989585

View Complete Trial Details & Eligibility at ClinicalTrials.gov